{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:29:14Z","timestamp":1792189754769,"version":"4.4.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006693","name":"Crouse Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.amjms.2026.01.002","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:11:48Z","timestamp":1767831108000},"page":"383-387","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical outcomes of cefepime extended infusions"],"prefix":"10.1016","volume":"371","author":[{"given":"Aaron","family":"Shaykevich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Kirchgraber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivayla","family":"Geneva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.amjms.2026.01.002_bib0001","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2165\/00003495-199447030-00007","article-title":"Cefepime","volume":"47","author":"Barradell","year":"1994","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.amjms.2026.01.002_bib0002","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/00006454-200103000-00034","article-title":"Empiric use of cefepime in the treatment of serious urinary tract infections in children","volume":"20","author":"Arrieta","year":"2001","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.amjms.2026.01.002_bib0003","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF03256641","article-title":"Cefepime: a review of its use in the management of hospitalized patients with pneumonia","volume":"2","author":"Chapman","year":"2003","journal-title":"Am J Respir Med"},{"issue":"4","key":"10.1016\/j.amjms.2026.01.002_bib0004","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1177\/10781552221080078","article-title":"Smaller but more frequent dosing of cefepime in the treatment of febrile neutropenia","volume":"28","author":"Okubo","year":"2022","journal-title":"J Oncol Pharm Pr"},{"issue":"6","key":"10.1016\/j.amjms.2026.01.002_bib0005","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/j.1875-9114.1994.tb04157.x","article-title":"Cefepime","volume":"14","author":"Hardin","year":"2012","journal-title":"Pharmacotherapy"},{"issue":"suppl_1","key":"10.1016\/j.amjms.2026.01.002_bib0006","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw172.1503","article-title":"Clinical evaluation of an alternate cefepime dosing protocol for gram-negative bloodstream and respiratory infections","volume":"3","author":"Gould","year":"2016","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1016\/j.amjms.2026.01.002_bib0007","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/1060028014564179","article-title":"Evaluating outcomes of alternative dosing strategies for cefepime","volume":"49","author":"Burgess","year":"2015","journal-title":"Ann Pharmacother"},{"issue":"8","key":"10.1016\/j.amjms.2026.01.002_bib0008","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/phar.2844","volume":"43","author":"Hong","year":"2023","journal-title":"Pharmacotherapy"},{"issue":"7","key":"10.1016\/j.amjms.2026.01.002_bib0009","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s40262-022-01137-y","article-title":"Clinical pharmacokinetics and pharmacodynamics of cefepime","volume":"61","author":"Pais","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"10.1016\/j.amjms.2026.01.002_bib0010","article-title":"Assessment of a PK\/PD target of continuous infusion beta-lactams useful for preventing microbiological failure and\/or resistance development in critically ill patients affected by documented gram-negative infections","volume":"10","author":"Gatti","year":"2021","journal-title":"Antibiot (Basel)"},{"issue":"3","key":"10.1016\/j.amjms.2026.01.002_bib0011","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/pbc.22051","article-title":"Optimizing bactericidal exposure for \u03b2-lactams using prolonged and continuous infusions in the pediatric population","volume":"53","author":"Courter","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10.1016\/j.amjms.2026.01.002_bib0012","first-page":"214","article-title":"A review of extended and continuous infusion beta-lactams in pediatric patients","volume":"27","author":"Imburgia","year":"2022","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.amjms.2026.01.002_bib0013","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1128\/AAC.01141-08","article-title":"Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia","volume":"53","author":"Nicasio","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.amjms.2026.01.002_bib0014","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/phar.2332","article-title":"Pharmacokinetics and pharmacodynamics of extended-infusion cefepime in critically ill patients receiving continuous renal replacement therapy: a prospective, open-label study","volume":"39","author":"Philpott","year":"2019","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.amjms.2026.01.002_bib0015","doi-asserted-by":"crossref","DOI":"10.1017\/ash.2023.179","article-title":"Cefepime extended infusion versus intermittent infusion: clinical and cost evaluation","volume":"3","author":"Khole","year":"2023","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"issue":"7","key":"10.1016\/j.amjms.2026.01.002_bib0016","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1128\/AAC.02365-12","article-title":"Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections","volume":"57","author":"Bauer","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl_1","key":"10.1016\/j.amjms.2026.01.002_bib0017","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw172.708","article-title":"Extended infusion versus traditional infusion cefepime in critically ill patients with documented Pseudomonas aeruginosa bacteremia or pneumonia","volume":"3","author":"Vela","year":"2016","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"10.1016\/j.amjms.2026.01.002_bib0018","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad170","article-title":"Clinical outcomes with extended versus intermittent infusion of anti-pseudomonal beta-lactams in patients with gram-negative bacteremia","volume":"10","author":"Tran","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.amjms.2026.01.002_bib0019","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1345\/aph.1R523","article-title":"Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study","volume":"47","author":"Arnold","year":"2013","journal-title":"Ann Pharmacother"},{"issue":"4","key":"10.1016\/j.amjms.2026.01.002_bib0020","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1177\/0018578719893377","article-title":"Impact of extended- versus intermittent-infusion cefepime on clinical outcomes in hospitalized patients","volume":"56","author":"Cosimi","year":"2020","journal-title":"Hosp Pharm"},{"issue":"4","key":"10.1016\/j.amjms.2026.01.002_bib0021","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.amjms.2026.01.002_bib0022","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/phar.2728","article-title":"Time to defervescence evaluation for extended- vs. standard-infusion cefepime in patients with acute leukemia and febrile neutropenia","volume":"42","author":"Crawford","year":"2022","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.amjms.2026.01.002_bib0023","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/IPC.0000000000000600","article-title":"Extended versus intermittent infusions of cefepime for the treatment of febrile neutropenia","volume":"26","author":"Przybylski","year":"2018","journal-title":"Infect Dis Clin Pract"},{"issue":"3","key":"10.1016\/j.amjms.2026.01.002_bib0024","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/1078155216687151","article-title":"Extended infusion compared to standard infusion cefepime as empiric treatment of febrile neutropenia","volume":"24","author":"Wrenn","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.amjms.2026.01.002_bib0025","article-title":"Efficacy of extended infusion of \u03b2-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients (BEATLE): a randomised, multicentre, open-label, superiority clinical trial","author":"Laporte-Amargos","year":"2024","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.amjms.2026.01.002_bib0026","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/phar.2744","article-title":"Use of therapeutic drug monitoring to characterize cefepime-related neurotoxicity","volume":"43","author":"Venugopalan","year":"2022","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.amjms.2026.01.002_bib0027","article-title":"Continuous infusion of cefepime and neurotoxicity: a retrospective cohort study","author":"Vercheval","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.amjms.2026.01.002_bib0028","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1177\/00185787241237142","article-title":"Case report: cefepime induced neurotoxicity following a change in infusion time","volume":"59","author":"Stratton","year":"2024","journal-title":"Hosp Pharm"},{"key":"10.1016\/j.amjms.2026.01.002_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijnurstu.2023.104673","article-title":"Peripheral intravenous catheter infection and failure: a systematic review and meta-analysis","volume":"151","author":"Marsh","year":"2024","journal-title":"Int J Nurs Stud"},{"issue":"12","key":"10.1016\/j.amjms.2026.01.002_bib0030","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1111\/jan.14565","article-title":"Peripheral intravenous catheter non-infectious complications in adults: a systematic review and meta-analysis","volume":"76","author":"Marsh","year":"2020","journal-title":"J Adv Nurs"},{"issue":"4","key":"10.1016\/j.amjms.2026.01.002_bib0031","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/1060028014566447","article-title":"Implementing extended-infusion cefepime as standard of care in a children\u2019s hospital","volume":"49","author":"Nichols","year":"2015","journal-title":"Ann Pharmacother"},{"issue":"4","key":"10.1016\/j.amjms.2026.01.002_bib0032","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/ppul.25817","article-title":"Evaluation of the safety of cefepime prolonged infusions in pediatric patients with cystic fibrosis","volume":"57","author":"Imburgia","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.amjms.2026.01.002_bib0033","article-title":"Characterizing cefepime neurotoxicity: a systematic review","volume":"4","author":"Appa","year":"2017"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962926000200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962926000200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:18:36Z","timestamp":1773418716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962926000200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0002962926000200"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2026.01.002","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes of cefepime extended infusions","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2026.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}